OVERVIEW

Strategies for Success in Atopic Dermatitis Care is organized by Prime Education, LLC.

Release Date: January 31, 2020
Expire Date: January 31, 2021

Accreditation:
Interprofessional Teams:
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physician Credit Designation Statement:
PRIME® designates this Enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistant Accreditation Statement:
PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioner Accreditation Statement:
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.5 contact hour (which includes 0 hour of pharmacology).

Pharmacist Accreditation Statement:
This Application-based activity has been approved for 0.5 contact hour (0.05 CEUs) by PRIME® for pharmacists.

Nurse Accreditation Statement:
PRIME® designates this activity for 0.5 contact hour.

Overview:
Listen in as Dr John Russell and a panel of renowned experts tackle pressing questions in atopic dermatitis (AD) care, offering their insightful perspectives to help you improve outcomes for your patients with AD.

Learn about:
• The latest clinical evidence and how it's shaping AD assessment, treatment, and management
• Pioneers in the field who are building bridges between specialty and primary care teams to optimize shared management of AD

Learning Objectives:
• Apply validated methods for atopic dermatitis (AD) diagnosis and disease severity assessment in adult and pediatric patients
• Evaluate current efficacy and safety evidence on new therapies for patients with moderate to severe AD
• Implement telehealth and other strategies to communicate with AD specialists to ensure that patients with moderate to severe disease receive needed therapies
• Incorporate methods to support patients with AD in accessing and adhering to needed therapies